ArticlePublic health challenges2026
Determinants of Second Dose Measles Vaccination Coverage in Somaliland: A Binary and Multivariate Logistic Regression Analysis.
Article in Public health challenges, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Understanding the predictors of second dose measles vaccination (MCV2) is essential for designing effective interventions to prevent outbreaks and reduce child mortality in Somaliland, thereby informing targeted public health strategies and policy decisions. Methods: A cross-sectional study was conducted using a national health survey of Somaliland. The study analyzed data from mothers regarding their children, selecting one child per household to ensure statistical independence. Binary and multivariate logistic regression models were applied to identify determinants of MCV2 coverage among 1417 eligible children. Results: The sample prevalence of MCV2 coverage was low at 33.5%. Significant predictors included maternal age, region, and prior receipt of DPT and BCG vaccinations. The adjusted odds ratio (AOR) MCV2 were higher among children of older mothers compared to those aged 15-19, specifically those aged 40-44 (AOR = 4.30; 95% confidence interval [CI]: 1.84-10.04) and 45-49 (AOR = 5.31; 95% CI: 1.55-18.16). Prior vaccination with DPT (AOR = 3.87; 95% CI: 2.92-5.15) and BCG (AOR = 2.47; 95% CI: 1.86-3.29) were also powerful predictors of MCV2 completion. Urban residence and maternal education were not significantly associated with coverage in the final adjusted model. Conclusion: The findings highlight the importance of maternal experience and the strength of the routine immunization system. Addressing systemic barriers through targeted interventions may encourage stakeholders to strengthen routine immunization programs, especially by utilizing prior healthcare contacts like DPT/BCG visits to potentially improve MCV2 follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.